GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aadi Bioscience Inc (NAS:AADI) » Definitions » 5-Year Yield-on-Cost %

AADI (Aadi Bioscience) 5-Year Yield-on-Cost % : 0.00 (As of Dec. 14, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Aadi Bioscience 5-Year Yield-on-Cost %?

Aadi Bioscience's yield on cost for the quarter that ended in Sep. 2024 was 0.00.


The historical rank and industry rank for Aadi Bioscience's 5-Year Yield-on-Cost % or its related term are showing as below:



AADI's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.57
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Competitive Comparison of Aadi Bioscience's 5-Year Yield-on-Cost %

For the Biotechnology subindustry, Aadi Bioscience's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aadi Bioscience's 5-Year Yield-on-Cost % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aadi Bioscience's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Aadi Bioscience's 5-Year Yield-on-Cost % falls into.



Aadi Bioscience 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Aadi Bioscience is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5

Aadi Bioscience  (NAS:AADI) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Aadi Bioscience 5-Year Yield-on-Cost % Related Terms

Thank you for viewing the detailed overview of Aadi Bioscience's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.


Aadi Bioscience Business Description

Traded in Other Exchanges
N/A
Address
17383 Sunset Boulevard, Suite A250, Pacific Palisades, CA, USA, 90272
Aadi Bioscience Inc is a clinical-stage biopharmaceutical company developing precision therapies for genetically-defined cancers. Aadi's primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes, where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site. It has one operating segment, which is the business of developing and commercializing proprietary therapeutic. Geographically, it is located in the United States.
Executives
David James Lennon director, officer: Chief Executive Officer C/O AADI BIOSCIENCE, INC., 17383 SUNSET BLVD, SUITE A250, PACIFIC PALISADES CA 90272
Neil Desai director, officer: See Remarks C/O AADI BIOSCIENCE, INC., 17383 SUNSET BLVD., SUITE A250, PACIFIC PALISADES CA 90272
Mohammad Hirmand director C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105
Scott M. Giacobello officer: Chief Financial Officer SOVEREIGN HOUSE, VISION PARK, HISTON, CAMBRIDGE X0 CB24 9BZ
Lorettta M Itri officer: Chief Medical Officer
Brendan Delaney officer: Chief Operating Officer 300 THE AMERICAN WAY, MORRIS PLAINS NJ 07950
Emma Reeve director C/O PAREXEL INTERNATIONAL CORPORATION, 195 WEST STREET, WALTHAM MA 02451
Karin M. Hehenberger director C/O CORONADO BIOSCIENCES, INC., 15 NEW ENGLAND EXECUTIVE PARK, BURLINGTON CO 01803
Richard E Maroun director C/O AADI BIOSCIENCE, INC., 17383 SUNSET BLVD., SUITE A250, PACIFIC PALISADES CA 90272
Caley Castelein director THOM. WEISEL HEALTHCARE VENTURES, ONE MONTGOMERY STREET, SAN FRANCISCO CA 94104
Lance E Thibault officer: Chief Financial Officer
Behzad Aghazadeh director, other: See Remarks C/O AVORO CAPITAL ADVISORS LLC, 110 GREENE STREET, SUITE 800, NEW YORK NY 10012
Venbio Select Advisor Llc director, other: See Remarks 110 GREENE STREET, SUITE 800, NEW YORK NY 10012
Anupam Dalal director 88 KEARNY STREET, SUITE 1800, SAN FRANCISCO CA 94108
Avoro Ventures Llc director, other: See Remarks 110 GREEN STREET, SUITE 800, NEW YORK NY 10012